Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hochwald, S. N.
Right arrow Articles by Conlon, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hochwald, S. N.
Right arrow Articles by Conlon, K. C.
Related Collections
Right arrow Surgery
Annals of Surgical Oncology 8:249-253 (2001)
© 2001 Society of Surgical Oncology


ORIGINAL ARTICLES

Laparoscopy Predicts Metastatic Disease and Spares Laparotomy in Selected Patients With Pancreatic Nonfunctioning Islet Cell Tumors

Steven N. Hochwald, MD, Martin R. Weiser, MD, Ramiro Colleoni, MD, Murray F. Brennan, MD and Kevin C. Conlon, MD

From the Department of Surgery (SNH), University of Florida College of Medicine, Gainesville, Florida; the Department of Surgery (MRW, MFB, KCC), Memorial Sloan-Kettering Cancer Center, New York, New York; and Escola Paulista de Medicina (RC), Universidade Federal de Sao Paulo, Sao Paulo, Brazil.

Correspondence: Address correspondence and reprint requests to: Kevin C. Conlon, MD, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; Fax: 212-717-3097.

Introduction: Our objective was to compare the efficacy of CT alone to CT followed by laparoscopy in determining resectability of pancreatic nonfunctioning islet (NFI) cell tumors.

Methods: A retrospective analysis from 1993 to 1999 revealed 48 patients who underwent surgical evaluation for NFI cell tumors. Of these, 34 (71%) patients underwent laparoscopy and CT for either diagnostic purposes or tumor staging. CT and laparoscopic criteria for curative resectability were defined and the sensitivity, specificity, and predictive value of both modalities in determining resectability were calculated.

Results: The most frequent tumor location and presenting symptoms were pancreatic head (n = 27, 56%) and abdominal pain (n = 31, 65%), respectively. Median tumor size was 4.0 cm. In the laparoscopy group, curative resection was performed in 20 cases (59%). CT followed by laparoscopy was more sensitive than CT alone in predicting resectability (93% vs. 50%, P = 0.03) with similar specificity (both 100%). The predictive value for tumor resectability was 74% for CT alone and 95% for CT followed by laparoscopy. Reasons for unresectability identified at laparoscopy but not indicated by CT were liver metastases (n = 6) or nodal disease (n = 1). Four of these patients were spared a laparotomy while the other three patients underwent surgical palliation and all are alive with disease (AWD). In those not undergoing laparoscopy (n = 14), curative resection was performed in 64% (n = 9). Four of these patients underwent resection, despite having metastases, and three are AWD.

Conclusions: NFI cell tumors of the pancreas present as large masses with frequent metastases. Despite metastatic disease, prolonged survival is often achieved with or without open surgical treatment. Laparoscopy can be used in diagnosis and accurately identifies metastases not seen on CT, thus sparing laparotomy in some patients.

Key Words: Laparoscopy • Pancreatic islet cell tumors • Resectability




This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
K. C. Conlon and R. L. McMahon
Minimally Invasive Surgery in the Diagnosis and Treatment of Upper Gastrointestinal Tract Malignancy
Ann. Surg. Oncol., October 1, 2002; 9(8): 725 - 737.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Society of Surgical Oncology.